Michael Egan

2.7k total citations · 2 hit papers
40 papers, 1.9k citations indexed

About

Michael Egan is a scholar working on Psychiatry and Mental health, Pharmacology and Physiology. According to data from OpenAlex, Michael Egan has authored 40 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Psychiatry and Mental health, 9 papers in Pharmacology and 9 papers in Physiology. Recurrent topics in Michael Egan's work include Schizophrenia research and treatment (8 papers), Alzheimer's disease research and treatments (6 papers) and Cholinesterase and Neurodegenerative Diseases (6 papers). Michael Egan is often cited by papers focused on Schizophrenia research and treatment (8 papers), Alzheimer's disease research and treatments (6 papers) and Cholinesterase and Neurodegenerative Diseases (6 papers). Michael Egan collaborates with scholars based in United States, France and Australia. Michael Egan's co-authors include Terry E. Goldberg, Tiffini Voss, James Kost, Jeffrey L. Cummings, Christine Furtek, Yuki Mukai, Pierre N. Tariot, Bruno Vellas, Paul Aisen and Erin Mahoney and has published in prestigious journals such as New England Journal of Medicine, American Journal of Psychiatry and Journal of Bone and Joint Surgery.

In The Last Decade

Michael Egan

37 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

2018 471 citations Michael Egan, James Kost et al. profile →
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

2019 380 citations Michael Egan, James Kost et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Egan United States	15	795	580	455	428	394	40	1.9k
Lyn Harper Mozley United States	17	774 1.0×	632 1.1×	368 0.8×	260 0.6×	288 0.7×	27	2.2k
C H van Dyck United States	9	515 0.6×	636 1.1×	314 0.7×	446 1.0×	968 2.5×	12	2.1k
Paul Ardayfio United States	14	920 1.2×	452 0.8×	336 0.7×	391 0.9×	359 0.9×	33	1.7k
Martin Tolar United States	17	1.1k 1.4×	382 0.7×	494 1.1×	465 1.1×	210 0.5×	33	1.7k
Emma L. Jones United Kingdom	7	929 1.2×	353 0.6×	324 0.7×	604 1.4×	228 0.6×	10	2.0k
Gary Tong United States	19	862 1.1×	354 0.6×	324 0.7×	802 1.9×	662 1.7×	35	2.1k
Robert Lai United Kingdom	25	1.6k 2.0×	447 0.8×	614 1.3×	675 1.6×	364 0.9×	61	2.7k
Johannes Streffer Belgium	30	1.6k 2.0×	491 0.8×	577 1.3×	1.1k 2.6×	536 1.4×	77	3.4k
D.M.A. Mann United Kingdom	19	1.4k 1.8×	498 0.9×	371 0.8×	807 1.9×	495 1.3×	36	2.2k
M. Axel Wollmer Germany	25	1.3k 1.6×	351 0.6×	291 0.6×	954 2.2×	474 1.2×	56	2.9k

Countries citing papers authored by Michael Egan

Since Specialization

Citations

This map shows the geographic impact of Michael Egan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Egan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Egan more than expected).

Fields of papers citing papers by Michael Egan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Egan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Egan. The network helps show where Michael Egan may publish in the future.

Co-authorship network of co-authors of Michael Egan

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Egan. A scholar is included among the top collaborators of Michael Egan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Egan. Michael Egan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miller, Paul, et al.. (2025). Interventions in Palliative Care Compatible With Cognitive Impairment: A Systematic Review. Review of General Psychology. 29(4). 426–441.

Mukai, Yuki, Robert Lupinacci, Stephen R. Marder, et al.. (2024). Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophrenia Research. 270. 37–43. 10 indexed citations

Strömberg, Bo, et al.. (2023). Assessment of canister degradation for the encapsulation of spent nuclear fuel: Key research issues encountered in recent regulatory reviews and government decision making in Sweden. Advances in geosciences. 62. 31–39. 1 indexed citations

Voss, Tiffini, James Kost, Christine Furtek, et al.. (2023). Progression from Prodromal Alzheimer’s Disease to Mild Alzheimer’s Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions. Journal of Alzheimer s Disease. 92(1). 341–348. 3 indexed citations

Sur, Cyrille, Katarzyna Adamczuk, David Scott, et al.. (2022). Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer’s disease. Molecular Imaging and Biology. 24(6). 862–873. 7 indexed citations

Egan, Michael, Yuki Mukai, Tiffini Voss, et al.. (2019). Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease. Alzheimer s Research & Therapy. 11(1). 68–68. 63 indexed citations

Egan, Michael, Xin Zhao, Ying Zhang, et al.. (2013). Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophrenia Research. 146(1-3). 224–230. 42 indexed citations

Egan, Michael, et al.. (2012). Magnitude of Impact of Executive Functioning and IQ on Episodic Memory in Schizophrenia. Biological Psychiatry. 71(6). 545–551. 20 indexed citations

Weickert, Thomas W., Terry E. Goldberg, Michael Egan, et al.. (2010). Relative Risk of Probabilistic Category Learning Deficits in Patients with Schizophrenia and Their Siblings. Biological Psychiatry. 67(10). 948–955. 33 indexed citations

10.

White, Michel, et al.. (2009). [Battlefield Blues: Ambivalence about treatment among military Veterans with depression].. PubMed. 55(8). 799–802. 2 indexed citations

11.

Goldberg, Terry E., et al.. (2008). Verbal and visual memory: Characterizing the clinical and intermediate phenotype in schizophrenia. Schizophrenia Research. 105(1-3). 78–85. 58 indexed citations

12.

Egan, Michael. (2004). Implementing A Successful Modular Design - PTC´S Approach. 49–57. 4 indexed citations

13.

Nicolson, Rob, Marge Lenane, Peter Gochman, et al.. (2003). Parental Schizophrenia Spectrum Disorders in Childhood-Onset and Adult-Onset Schizophrenia. American Journal of Psychiatry. 160(3). 490–495. 75 indexed citations

14.

Egan, Michael, et al.. (2000). Heritability estimates for independent domains of cognitive dysfunction in schizophrenia. Schizophrenia Research. 41(1). 89–90. 1 indexed citations

15.

Adler, Caleb M., Anil K. Malhotra, Igor Elman, et al.. (1999). Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia. American Journal of Psychiatry. 156(10). 1646–1649. 271 indexed citations

16.

Egan, Michael, et al.. (1994). How to create successful change Leadership for quality. Journal for Quality and Participation. 17. 2 indexed citations

17.

Chrapusta, Stanisław J., Michael Egan, Joseph M. Masserano, & Richard Jed Wyatt. (1994). Dopamine release in the rat cerebellum and hippocampus: a tissue 3-methoxytyramine study. Brain Research. 655(1-2). 271–275. 7 indexed citations

18.

Chrapusta, Stanisław J., Farouk Karoum, Michael Egan, & Richard Jed Wyatt. (1993). Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not γ-butyrolactone-resistant dopamine release. European Journal of Pharmacology. 233(1). 135–142. 5 indexed citations

19.

Egan, Michael, et al.. (1993). Serum Creatine Phosphokinase Elevations in Patients with Tardive Dyskinesia. The British Journal of Psychiatry. 162(4). 551–553. 8 indexed citations

20.

Egan, Michael, Thomas M. Hyde, David Tirschwell, Joel E. Kleinman, & Daniel R. Weinberger. (1992). Laterality of appendicular tardive dyskinesia in chronic schizophrenia. Biological Psychiatry. 31(11). 1098–1109. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact